risedronate / Generic mfg. - LARVOL DELTA

Risedronate attenuates renal fibrosis by targeting prenylation-dependent RhoA/ROCK1 and ERK/NF-κB signaling. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Moreover, immunocytochemistry suggested that RIS inhibits protein prenylation-dependent expression of p-ERK 1/2, RhoA, and ROCK1 in NRK-52E cells. Indeed, the study findings indicated that RIS treatment modulated renal fibrosis by targeting prenylation-dependent RhoA/ROCK1 and ERK/NF-κB signaling axis, holding the clinical promise in CKD management."

Journal • Chronic Kidney Disease • Fibrosis • Immunology • Nephrology • Renal Disease • CTGF • IL6 • RHOA • TGFB1 • TNFA

Transdermal delivery of risedronate via spanlastics for osteoporosis: formulation optimization, skin deposition, and pharmacokinetic assessment. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Risedronate-loaded spanlastics represent a promising transdermal delivery system that overcomes oral limitations by improving bioavailability and skin permeation. Still, further investigation of risedronate-loaded spanlastics gel in in vivo pharmacodynamics studies is necessary to confirm its potential in the long-term treatment of osteoporosis."

Journal • PK/PD data • Osteoporosis • Rheumatology

Bisphosphonate-related ocular adverse events: a pharmacovigilance study based on the FAERS database. (PubMed, Endocr Connect) - "Among 6,965 ocular AE reports for five BPs (alendronate, zoledronate, pamidronate, risedronate, and ibandronate), 136 positive signals were identified, predominantly unlisted in drug labels. This study identifies high-risk and novel ocular AEs related to BPs. These findings warrant further validation in future studies."

Adverse events • Journal • Age-related Macular Degeneration • Cataract • Glaucoma • Macular Degeneration • Ocular Inflammation • Ophthalmology • Retinal Disorders

Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis (clinicaltrials.gov) - P=N/A | N=40 | Recruiting | Sponsor: Khyber Medical University Peshawar

New trial • Osteoporosis • Rheumatology

γ9δ2 T cells detect mevalonate diphosphate via BTN3A3. (PubMed, Cell Mol Life Sci) - "LC-MS showed that 6-FM-treated CHO-K1 cells accumulated substantial MPP while risedronate, an inhibitor of farnesyl diphosphate synthase, primarily increased DMAPP/IPP...Both BTN2A1 + BTN3A3-transfected CHO-K1 cells and BTN3A1 knockout K562 cells could detect 6-FM, despite their absence of BTN3A1. Our findings provide evidence that MPP functions as a natural ligand of BTN3A3 and establish a foundation for elucidating biological functions of BTN3A3 complementary to the established BTN3A1 pathway."

Journal • Oncology • Targeted Protein Degradation • BTN2A1 • BTN3A1

Semaglutide-Induced FATAL Acute Necrotizing Pancreatitis Complicated by ARDS and Septic Shock (ACG 2025) - "Medications included lisinopril, risedronate, rosuvastatin, alprazolam, and semaglutide, started 1–2 weeks earlier, with the last dose 2 days before presentation...Hemodialysis was initiated for acute renal failure, and ventricular tachycardia was managed with amiodarone and cardioversion...After family discussions, a DNR/DNI order was established, and she succumbed to septic shock and ARDS, likely triggered by semaglutide-induced pancreatitis. This case highlights the rare but severe risk of semaglutide-associated necrotizing pancreatitis, particularly in patients with pre-existing pancreatic pathology. Clinicians should exercise caution when prescribing GLP-1 receptor agonists to such patients and monitor closely for early pancreatitis symptoms to prevent catastrophic outcomes.Figure: Acute pancreatitis with proximal pancreatic hypoenhancement, indicating necrosis, without peripancreatic fluid collections.Figure: Coronal view showing Acute pancreatitis with proximal..."

Acute Kidney Injury • Acute Respiratory Distress Syndrome • Anesthesia • Cardiovascular • Diabetes • Diabetic Nephropathy • Dyslipidemia • Endocrine Disorders • Hypertension • Metabolic Disorders • Mood Disorders • Osteoporosis • Pancreatic Cancer • Pancreatitis • Psychiatry • Pulmonary Disease • Renal Disease • Respiratory Diseases • Rheumatology • Septic Shock • Ventricular Tachycardia

Distribution of Fracture Risk Status and Osteoporosis Treatment Use Among Postmenopausal Women with Osteoporosis in the United States (ACR Convergence 2025) - "Anabolic therapy (AT), the RANKL inhibitor denosumab (Dmab), and intravenous zoledronic acid (ZOL) are recommended as initial therapy for patients at very high risk (VHR) for fracture...OP medications included oral bisphosphonates (BPs; alendronate, risedronate, ibandronate), Dmab, ZOL, and AT (romosozumab, parathyroid hormone analogues [teriparatide, abaloparatide])... More than 1/3 of untreated PMO women are at VHR for fracture and eligible for ATs, Dmab, or ZOL in accordance with treatment guidelines. Among treated VHR PMO women, over half were treated with oral BP in contradiction with current treatment guidelines. Only a small percentage were treated with ATs, which clinical studies have shown are the most effective initial therapy for PMO women at VHR for fracture."

Clinical • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rare Diseases • Rheumatology

Breaking Bones, Breaking Hearts: A FAERS Perspective on Osteoporosis Medications (ACR Convergence 2025) - "Previous studies suggest that romosozumab (ROM) is most strongly associated with major adverse cardiovascular events (MACE), while denosumab (DMB) and teriparatide (TPT) have shown associations with select cardiovascular events in some reports [1–3]. Evidence for alendronate (ALN) and zoledronic acid (ZOL) is mixed, with some studies linking ZOL to atrial fibrillation (A-fib) [4–5]. Limited data exist for risedronate (RIS) and abaloparatide (ABA), with no consistent evidence of increased cardiovascular risk [1,4]... We found that among the drugs considered, only ROM was associated with increased ROR for all MACE outcomes. In contrast, DMB and ABA demonstrated relatively low cardiovascular risk signals across most outcomes. ZOL showed notable positive associations with both stroke and A-fib, while ALN was linked to increased reporting of A-fib and CF.Our findings suggest that a patient's individual risk for MACE should be considered when choosing osteoporosis drugs."

Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure • Musculoskeletal Diseases • Myocardial Infarction • Orthopedics • Osteoporosis • Rheumatology

RISEDRONATE AS AN UNDERRECOGNIZED CAUSE OF INCREASED OSMOLAR GAP (CHEST 2025) - "Both the patient and his partner denied ingestion of aspirin, acetaminophen, rubbing alcohol, or antifreeze. This case underscores acetone's potential role in increasing the osmolar gap, particularly in malnourished patients with alcoholic ketoacidosis. Recognizing this association is crucial for timely diagnosis and effective ICU management."

Addiction (Opioid and Alcohol) • Ataxia • CNS Disorders • Depression • Metabolic Disorders • Movement Disorders • Otorhinolaryngology • Psychiatry • Sleep Disorder

Association of Osteoporosis and Bone-Strengthening Medications with Postoperative Outcomes Following Transforaminal Lumbar Interbody Fusion. (PubMed, World Neurosurg) - "Osteoporosis is linked to higher reoperation and medical complications following lumbar fusion. Although osteoporosis medications did not significantly alter reoperation risk, their potential role in perioperative optimization requires further investigation."

Journal • Cardiovascular • Hematological Disorders • Infectious Disease • Nephrology • Orthopedics • Osteoporosis • Pneumonia • Respiratory Diseases • Rheumatology • Thrombosis

Engineering a BMP2-risedronate complex with sustained release for osteoporosis therapy. (PubMed, Arch Pharm Res) - "In vivo studies confirmed that fabricated BMP2-risedronate complex loaded in hydrogels promotes sustained BMP2 release and, in combination with risedronate, enhances osteogenic efficacy. These findings suggest that the BMP2-risedronate ionic complex is a promising candidate for localized BMP2 delivery in osteogenesis therapy."

Journal • Osteoporosis • Rheumatology • BMP2

Preclinical Study of Pain Neuropeptide Expression in Murine Sensory Neurons Induced by Irradiated Osteoclasts in the Context of Stereotactic Body Radiation Therapy. (PubMed, Cells) - "Osteoclasts differentiation and activity were inhibited using osteoprotegerin (OPG) and risedronate...These findings suggest that radiation enhances osteoclast activity and promotes pain signaling. Osteoclast inhibitors may represent a therapeutic strategy to reduce CWP and improve quality of life."

Journal • Preclinical • Lung Cancer • Oncology • Pain • Solid Tumor • CTSK • MMP9 • TNFRSF11A • TNFRSF11B • TRAP

Pharmacovigilance-Based Identification and Mechanistic Exploration of Periodontitis-Related Drugs. (PubMed, J Clin Periodontol) - "This study uncovered the association between drug and periodontitis and highlighted VEGFA as a potential molecular mediator. Further studies are needed to confirm causality."

Adverse events • Journal • Dental Disorders • Inflammation • Periodontitis

Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women (clinicaltrials.gov) - P4 | N=149 | Completed | Sponsor: Dong-A ST Co., Ltd. | Active, not recruiting ➔ Completed

Trial completion • Osteoporosis • Rheumatology

Osteonecrosis of the external auditory canal in two patients on denosumab therapy. (PubMed, JBMR Plus) - "A trial of risedronate was commenced with reduction of bone markers and epithelization of the auditory canal. Currently, there is no recommendation for routine auditory canal assessment prior to or during antiresorptive treatment. However, sequencing off established denosumab use with follow-on treatment to mitigate potential rapid bone loss needs to be considered."

Journal • Infectious Disease • Inflammation • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Renal Calculi • Rheumatology

Inpatient rehabilitation fracture liaison service (FLS) improves outcomes for secondary prevention of hip fractures. (PubMed, Bone Rep) - "The prevalence of initiation and adherence to anti-osteoporotic treatments, including alendronate, risedronate, zoledronate, denosumab, romosozumab, and teriparatide, was compared between the rehabilitation FLS initiative patients and patients from other hospitals without FLS. The FLS in the inpatient rehabilitation setting was found to be highly effective in improving time to treatment initiation and adherence rates to prescribe anti-osteoporosis therapy. These findings demonstrate the role of FLS in addressing the osteoporosis treatment gap following fragility hip fracture."

Journal • Musculoskeletal Diseases • Oncology • Orthopedics • Osteoporosis • Rheumatology

Eruptive acral syringomas: A case report and review of literature. (PubMed, SAGE Open Med Case Rep) - "We present a case of a 43-year-old woman with Vogt-Koyanagi-Harada syndrome, on adalimumab, methotrexate, and risedronate, who developed pruritic, skin-colored papules on the dorsal hands. Treatment is challenging due to their dermal depth and recurrence risk, with lasers and retinoids among the options. This case highlights the diagnostic complexity of acral eruptive syringomas."

Journal • Dermatology • Oncology

Encapsulating Pt NCs with an AIE effect into a metal-organic framework as a novel fluorescence nanoprobe for discriminatively detecting bisphosphonate drugs. (PubMed, Anal Bioanal Chem) - "More importantly, our designed Pt NCs@ZIF-8-based nanoprobe also presents excellent discrimination capability toward four structurally similar BPs-Etidronate, Clodronate, Alendronate, and Risedronate, as confirmed by statistical techniques such as principal component analysis (PCA) and hierarchical clustering analysis (HCA). Finally, the proposed Pt NCs@ZIF-8 nanoprobe was successfully applied to quantify the labeled amount percentage of commercially available Sodium Risedronate and Sodium Alendronate tablets, achieving satisfactory limits of detection (LOD) spanning from 1.2 to 8.8 µM and excellent recovery ranging from 97.50% to 102.6%. This work not only provides a novel and convenient strategy for detecting and distinguishing BPs but also demonstrates the potential application of metal-organic frameworks encapsulating metal nanoclusters with AIE properties in pharmaceutical quality control."

Journal

Prescription Trends by Orthopedic Surgery Provider: Review of the Medicare Part D Prescribers - by Provider and Drug, 2013-2021. (PubMed, Orthopedics) - "In line with national guidelines, claims for NSAIDs are increasing and claims for opioid pain medications and AOMs are decreasing. Claims for outpatient antibiotics are increasing, which is of significant concern, given renewed focus on antibiotic stewardship."

Journal • Medicare • Reimbursement • Review • US reimbursement • Orthopedics • Pain

Promising efficacy of nitrogen-containing bisphosphonates against the infection of Cryptosporidium spp. (PubMed, Int J Parasitol Drugs Drug Resist) - "This study determined the anti-Cryptosporidium effect of three nitrogen-containing bisphosphonates risedronate, ibandronate, and zoledronate through both in vitro and in vivo experiments. was assessed. Risedronate show promising effect for further development of new anticryptosporidial drugs."

Journal • Infectious Disease • IL2 • IL4 • TNFA

Drug repurposing for osteoarthritis disease modification in the Early 21st Century. (PubMed, Connect Tissue Res) - "Several repurposed drugs, predominantly those affecting inflammation (e.g. Methotrexate, Adalimumab), metabolism (e.g. Metformin, Liraglutide) and bone homeostasis (e.g. Risedronate, Clodronate) have been investigated for OA. The future of OA drug repurposing will likely be shaped by advancements in high-throughput screening, artificial intelligence-driven drug discovery, and strategies that align treatments with patient-specific disease mechanisms. By integrating these innovations, drug repurposing holds potential to deliver DMOADs and improve patient outcomes worldwide."

Journal • Immunology • Inflammation • Metabolic Disorders • Orthopedics • Osteoarthritis • Pain • Rheumatology

A Systematic Review on the Efficacy of Bisphosphonates on Osteogenesis Imperfecta. (PubMed, Cureus) - "This manuscript examines the comparative effectiveness of alendronate, neridronate, olpadronate, pamidronate, risedronate, and zoledronic acid on fracture rate reduction, increases in lumbar spine (LS) bone mineral density (BMD), and adverse effects compared to placebos and each other. This analysis highlighted the efficacy and safety profiles of bisphosphonates in the treatment of OI. Neridronate and olpadronate were highly effective in reducing fracture risk and rates, and olpadronate demonstrated superior efficacy in reducing fracture rates. Future research should focus on large, diverse samples, detailed fracture and BMD data, and comparisons across multiple bisphosphonates to refine treatment strategies."

Journal • Review • Gastrointestinal Disorder • Genetic Disorders • Musculoskeletal Diseases • Orthopedics

Safety and efficacy of antiresorptive treatments in patients with obesity: a registry-based study. (ENDO 2025) - "A total of 5412 (46.6%) patients purchased an anti-resorptive agent: 3370 (62.2%) alendronate, 1562 (28.9%) risedronate, 270 (5%) zoledronic acid, and 210 (3.9%) denosumab. Our findings suggest that anti-resorptive agents reduce osteoporotic fractures and mortality among obese patients, offering valuable insights for treatment strategies in this vulnerable population."

Clinical • Genetic Disorders • Musculoskeletal Diseases • Obesity • Orthopedics • Osteoporosis • Rheumatology

Recurrent metatarsal, scapular and acromial fractures during Denosumab therapy in Adult-onset Hypophosphatasia with a pathogenic variant of the ALPL gene and a variant of uncertain significance of the ATRIP Gene (ENDO 2025) - "She was initially started on risedronate at age 61y but due to continued non-traumatic metatarsal fractures teriparatide was recommended...She has been offered treatment with Asfotase alfa (AA). Adult-onset HPP was recognized in a 66-yo female who presented with acromial, scapular and recurrent metatarsal fractures while on denosumab therapy for 4 y for osteoporosis...AA, a human recombinant enzyme replacement therapy was approved for HPP in 2015. Treatment with anabolic agents such as teriparatide and romosozumab has been reported while anti-resorptives such as bisphosphonates and denosumab are contraindicated."

Clinical • Addiction (Opioid and Alcohol) • Endocrine Disorders • Fibromyalgia • Growth Hormone Deficiency (Adult) • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Osteoporosis • Pain • Rheumatology • ALPL • ATRIP

Primary Hyperparathyroidism in a Patient with Osteogenesis Imperfecta Type I and Osteoporosis (ENDO 2025) - "She was diagnosed with osteoporosis after menopause in her early 50s and was started on risedronate...Although some treatments for osteoporosis and OI overlap, we have limited, long-term data on denosumab use...Routine measurement of calcium should be done in patients with OI as these conditions can occur and the diagnosis and opportunity for treatment can be missed. Additional studies are needed to establish this concurrence."

Clinical • Endocrine Disorders • Genetic Disorders • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Otorhinolaryngology • Rheumatology